Skip to main content

NHL

5
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 7 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
2 programs
2
90Y-hLL2Phase 1/21 trial
veltuzumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT00421395Completed59Est. Oct 2007
NCT00546793Completed32Est. Mar 2013
Indapta Therapeutics
Indapta TherapeuticsCA - San Francisco
1 program
1
IDP-023Phase 1/21 trial
Active Trials
NCT06119685Recruiting128Est. Dec 2029
Boston Immune Technologies & Therapeutics
1
BITR2101Phase 11 trial
Active Trials
NCT06385522Not Yet Recruiting37Est. Feb 2027
Cullinan Therapeutics
Cullinan TherapeuticsMA - Cambridge
1 program
1
CLN-978Phase 11 trial
Active Trials
NCT05879744Active Not Recruiting90Est. Apr 2027
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
3 programs
90Y-hLL2PHASE_1_2
90Y-hLL2PHASE_1_2
veltuzumabPHASE_1_2Monoclonal Antibody
Precision BioSciences
1 program
anti-CD19 CAR NKPHASE_11 trial
Active Trials
NCT04639739Unknown9Est. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Indapta TherapeuticsIDP-023
Kite Pharmaveltuzumab
Kite Pharma90Y-hLL2
Boston Immune Technologies & TherapeuticsBITR2101
Cullinan TherapeuticsCLN-978
Precision BioSciencesanti-CD19 CAR NK

Clinical Trials (6)

Total enrollment: 355 patients across 6 trials

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Start: Oct 2023Est. completion: Dec 2029128 patients
Phase 1/2Recruiting

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Start: Jan 2008Est. completion: Mar 201332 patients
Phase 1/2Completed

Safety Study of NHL With 90Y-hLL2 IgG

Start: Aug 2002Est. completion: Oct 200759 patients
Phase 1/2Completed

A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System

Start: Aug 2025Est. completion: Feb 202737 patients
Phase 1Not Yet Recruiting

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Start: May 2023Est. completion: Apr 202790 patients
Phase 1Active Not Recruiting

Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma.

Start: Dec 2020Est. completion: Dec 20239 patients
Phase 1Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 355 patients
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.